Telaprevir for Genotype 1 Hepatitis C in HIV-Coinfected Patients
In a small phase II study of telaprevir versus placebo in combination with standard HCV therapy, SVR rates were higher among telaprevir recipients, with no detrimental effects on HIV control.
In patients on suppressive antiretroviral therapy, greater CD8-cell activation and higher interleukin-6 level are associated with functional impairment.
In aging HIV-uninfected individuals, immune activation and inflammatory markers are associated with declines in physical function and increased frailty. Given evidence that, despite years of suppressive antiretroviral therapy (ART), HIV-infected patients have higher levels of T-cell activation and inflammation than HIV-uninfected individuals, investigators examined whether these markers are associated with functional impairment in HIV-infected patients.
HIV-Mediated CD8 Encephalitis: Adding Fuel to the Immune-Dysregulation Fire
Clinicians describe a CNS inflammatory complication in HIV-infected patients on long-term antiretroviral therapy whose outcomes ranged from death to total recovery with adjunctive glucocorticoids.
HCV Testing in HIV-Infected MSM: Once Is Not Enough
A high incidence of HCV seroconversion in this population implies that repeat HCV testing should be routinely performed, particularly in individuals with high-risk sexual behaviors.
Higher Tenofovir Trough Concentrations and Renal Dysfunction
High trough levels of tenofovir, seen in half the patients taking the drug, were associated with renal impairment.
Results presented at CROI 2013 underscore some of the barriers to pre-exposure prophylaxis.
Studies presented at CROI 2013 remind us that, as prevention goes biological, human behavior still determines outcomes.
2-Week vs. 4-Week Rotations for Inpatient Teaching Physicians: A Randomized Trial
Length of stay and readmissions were unaffected, but attending physician burnout was more likely with 4-week rotations.
A huge, well-controlled study affirms that HIV infection, whether treated or not, is an independent cardiovascular risk factor.
Despite much study, the connection between HIV and coronary heart disease (CHD) remains tantalizingly difficult to confirm, in part because few studies have been able to definitively control for all the more traditional cardiovascular risk factors. Now, researchers have followed up a large prospective cohort of more than 82,000 veterans (mean age, 48; 97% men; 48% black) from 2003 through 2009 for development of myocardial infarction (MI). About one third of participants were HIV infected, and at baseline about half of these individuals were receiving antiretroviral therapy (ART).
Hepatitis Flares and Mortality in Patients with HIV and Hepatitis Virus Coinfection
Pretreatment inflammation and coagulation biomarkers are associated with increased risk for these important complications after initiation of antiretroviral therapy.